Precision Biologics to Present PB-223 ADC's Cancer-Efficacy at the 6th ACE Drug Discovery Summit Precision Biologics, led by CEO Philip M. Arlen, will showcase the effectiveness of its PB-223 ADC targeting cancer at the 6th ACE Drug Discovery Summit in London.

Precision Biologics to Present PB-223 ADC's Cancer-Efficacy at the 6th ACE Drug Discovery Summit #London #United_Kingdom #Precision_Biologics #PB-223_ADC #Philip_Arlen